Мы используем Cookies Этот веб-сайт использует cookie-файлы, чтобы предлагать вам наиболее актуальную информацию. Просматривая этот веб-сайт, Вы принимаете cookie-файлы.
No significant determinants of positive 13C-UBT given negative serology could be identified.
2
In this study, the safety and the accuracy of UBT were evaluated.
3
Results: Correlation between delta 13C-UBT and dyspepsia score was not found.
4
Acidification of the stomach did not prevent false negative UBT results.
5
Low UBT values were associated with the risk of gastric cancer.
6
Agreement between UBT and HpSA diminished throughout the follow-up.
7
Only one patient in UBT group resorted to hysterectomy.
8
Methods: Our study involved 413 consecutive patients who had undergone esophagogastroduodenal examination and the UBT test.
9
A standardized questionnaire was applied to identify factors which could explain discrepant results of 13C-UBT and serology.
10
A second endoscopy was performed if UBT results showed evidence of treatment failure or H. pylori recurrence.
11
UBT was well tolerated and none of the 492 patients had any systemic or allergic-type adverse reaction.
12
Five of the children had follow-up UBTs and four were negative consistent with the diagnosis of false-positive UBT.
13
The UBT recovered in all but one subject by the fourth day post-PPI and in all subjects by day 14.
14
Conclusions: The 13C-UBT is a reliable semiquantitative test to assess H. pylori density and the activity and degree of gastritis.
15
Thirty-two patients with UBT-defined treatment failures or H. pylori recurrences at any point during the 9-month follow-up underwent a second endoscopy.
16
Four weeks after finishing medication, the 13C-UBT was repeated in all cases and endoscopy was offered to patients with peptic ulcers.